Severe Renal Impairment

DrugDrug NameDrug Description
DB12688Moxetumomab PasudotoxCD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the _Pseudomonas_ exotoxin A (PE38) which does not have the cell-binding portion.[A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.[A38864] It was developed by Astra Zeneca and FDA approved on September 13, 2018, after being granted the status of Fast Track, Priority Review and Orphan Drug designations.[L4568]
DrugDrug NamePhaseStatusCount
DB15059Aprocitentan1Completed1
DB00243Ranolazine1Terminated1
DB09183Dasabuvir3Completed1
DB09296Ombitasvir3Completed1
DB09297Paritaprevir3Completed1
DB00811Ribavirin3Completed1
DB00503Ritonavir3Completed1
DB08860Pitavastatin4Completed1